Immutep Limited – NASDAQ:IMMP
Immutep Limited stock price today
$1.76
-0.24
-12.44%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Immutep Limited stock price monthly change
-12.99%
month
Immutep Limited stock price quarterly change
-12.99%
quarter
Immutep Limited stock price yearly change
-18.29%
year
Immutep Limited key metrics
Market Cap | 289.05M |
Enterprise value | 55.92M |
P/E | -5.33 |
EV/Sales | 17.60 |
EV/EBITDA | -4.42 |
Price/Sales | 51.25 |
Price/Book | 2.12 |
PEG ratio | 0.09 |
EPS | 0.12 |
Revenue | 7.32M |
EBITDA | -73.19M |
Income | -67.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -430.64% |
Oper. margin | -300.79% |
Gross margin | -166.52% |
EBIT margin | -300.79% |
EBITDA margin | -999.21% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmutep Limited stock price history
Immutep Limited stock forecast
Immutep Limited financial statements
Average Price Target
$7
Potential upside: 297.72%
Analysts Price target
Financials & Ratios estimates
| Jun 2021 | 791.25K | -16.22M | -2050.11% |
|---|---|---|---|
| Dec 2021 | 2.08M | -16.27M | -781.26% |
| Jun 2022 | 2.63M | -15.94M | -605.69% |
| Jun 2023 | 1.82M | -19.27M | -1058.85% |
| Dec 2021 | 120207148 | 11.32M | 9.42% |
|---|---|---|---|
| Jun 2022 | 102169550 | 8.09M | 7.92% |
| Dec 2022 | 86009304 | 9.32M | 10.84% |
| Jun 2023 | 147448990 | 10.97M | 7.45% |
| Jun 2022 | -30.22M | -6K | -68K |
|---|---|---|---|
| Mar 2023 | -14.16M | -1K | -46K |
| Jun 2023 | -8.34M | -3K | 76.19M |
| Mar 2024 | 0 | -559K | -55K |
Immutep Limited alternative data
| Mar 2024 | 41 |
|---|---|
| Apr 2024 | 41 |
| May 2024 | 41 |
| Jun 2024 | 41 |
| Jul 2024 | 41 |
Immutep Limited other data
0.02%
-0.47%
of IMMP is owned by hedge funds
157.82K
-3.98M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2013 6 Aug 2013 | Q4 2013 Earnings Call Transcript |
| Q1 2013 24 Apr 2013 | Q1 2013 Earnings Call Transcript |
| Q2 2013 7 Mar 2013 | Q2 2013 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Marc Voigt (1973) Chief Executive Officer, MD, Chief Financial Officer, Chief Bus. Officer & Executive Director | $400,490 |
Dr. Frederic Triebel M.D., Ph.D. (1955) Chief Scientific Officer & Chief Medical Officer | $398,120 |
Ms. Deanne Miller LLB (1977) Chief Operating Officer, Gen. Counsel & Joint Company Sec. | $262,930 |
Immutep Limited: Continuing To Make The Case For Eftilagimod
Immutep: Realizing The Expected Catalysts, With More To Come
Immutep: Upcoming Signals For 2024 (Maintain Buy)
Immutep: Nipping At The Heels Of LAG3.Is It Impressive Enough?
Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
Immutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or Takeout
-
What's the price of Immutep Limited stock today?
One share of Immutep Limited stock can currently be purchased for approximately $1.76.
-
When is Immutep Limited's next earnings date?
Unfortunately, Immutep Limited's (IMMP) next earnings date is currently unknown.
-
Does Immutep Limited pay dividends?
No, Immutep Limited does not pay dividends.
-
How much money does Immutep Limited make?
Immutep Limited has a market capitalization of 289.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 9.59% to 3.84M US dollars.
-
What is Immutep Limited's stock symbol?
Immutep Limited is traded on the NASDAQ under the ticker symbol "IMMP".
-
What is Immutep Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Immutep Limited?
Shares of Immutep Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Immutep Limited's key executives?
Immutep Limited's management team includes the following people:
- Mr. Marc Voigt Chief Executive Officer, MD, Chief Financial Officer, Chief Bus. Officer & Executive Director(age: 52, pay: $400,490)
- Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer & Chief Medical Officer(age: 70, pay: $398,120)
- Ms. Deanne Miller LLB Chief Operating Officer, Gen. Counsel & Joint Company Sec.(age: 48, pay: $262,930)
-
How many employees does Immutep Limited have?
As Jul 2024, Immutep Limited employs 41 workers.
-
When Immutep Limited went public?
Immutep Limited is publicly traded company for more then 13 years since IPO on 19 Apr 2012.
-
What is Immutep Limited's official website?
The official website for Immutep Limited is immutep.com.
-
Where are Immutep Limited's headquarters?
Immutep Limited is headquartered at Australia Square, Sydney, NSW.
-
How can i contact Immutep Limited?
Immutep Limited's mailing address is Australia Square, Sydney, NSW and company can be reached via phone at +61 2 8315 7003.
-
What is Immutep Limited stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Immutep Limited in the last 12 months, the avarage price target is $7. The average price target represents a 297.72% change from the last price of $1.76.
Immutep Limited company profile:
Immutep Limited
immutep.comExchange:
NASDAQ
Full time employees:
41
Industry:
Biotechnology
Sector:
Healthcare
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Australia Square
Sydney, NSW 2000
Sydney, NSW 2000
CIK: 0001506184
ISIN: US45257L1089
CUSIP: 45257L108
